NMRA — Neumora Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $120.66m
- -$128.69m
Annual cashflow statement for Neumora Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -99.3 | -237 | -131 | -236 | -244 |
| Depreciation | |||||
| Non-Cash Items | 75.5 | 162 | 22.4 | 80.9 | 37.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.12 | -0.961 | -6.95 | -8.9 | 22.6 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -26.8 | -75.4 | -115 | -163 | -183 |
| Capital Expenditures | -1.3 | -0.817 | -13.5 | -4.71 | -0.775 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -9.94 | 0 | -155 | 69.1 | -69.8 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -11.2 | -0.817 | -168 | 64.4 | -70.6 |
| Financing Cash Flow Items | 0 | -1.14 | -0.744 | -3.8 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 230 | 294 | 116 | 232 | 21.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 192 | 217 | -167 | 133 | -232 |